We’re creative thinkers, and we’re here to help ambitious businesses deliver meaningful value. We’ve spent a lifetime building our reputations by delivering exceptional outcomes and we will never compromise on our simple approach based on diligence, judgement and ethics. Together, our entrepreneurial and personable team remains passionate about playing a key part in shaping the great companies of the future.
Chris Brinsmead CBE – Chairman
Chris worked in the Pharmaceutical industry for over thirty years, holding executive leadership roles with ICI, Zeneca and Astrazeneca. He is a Non Executive director of several private and listed companies including UDG plc and The Wesleyan Assurance Society. He is Chairman at Proveca Ltd and a Member of Council at Imperial College. He co-founded Bamburgh Capital (renamed from Diagnostic Capital in 2016) with David Evans and Alex Clarkson in 2010. Chris was appointed a CBE in January 2015.
Alex Clarkson ACA, MCSI
Alex is an experienced corporate financier, investor and co-founder. Having spent his early years in Transaction Services and Due Diligence with PwC, he has since developed a broad range of advisory skills and trusted relationships across capital markets with a range of UK equity investors, private equity firms, high net worth individuals and banks. After PwC, Alex spent three years in Corporate Finance as part of the respected Brewin Dolphin Corporate Advisory and Broking team. Alex has been key to establishing and creating value in numerous companies including Zeus Group and Collagen Solutions.
David Evans CA
David is an experienced Chairman and investor. He has a strong track record in taking companies through the IPO process and delivering significant value to shareholders. Most recently achieved successful exits for Sirigen (upto 4x value uplift), BBI (4x) and Scipac (exit achieved within 12 months of joining) as well as creating substantial uplifts in value during his tenure as Chairman for IDS (20x), Optibiotix Health (10x), DxS (10x), Scancell (5x) and Epistem (3x). He has considerable M&A experience including cross-border deals with over 20 transactions completed in the diagnostics/life sciences space. He is currently Chairman of Collagen Solutions plc and Omega Diagnostics plc. Previous roles include CEO of Axis-Shield plc and Chairman of Premaitha Health plc. Having co-founded Bamburgh Capital, David remains a shareholder and consultant.
Michael Parkinson FCA
Michael has a broad range of experience including 13 years as a respected analyst and corporate broker at Brewin where he played a pivotal role in a number of successful IPOs and secondary fund raisings. Prior to Brewin, Michael spent several years in Transaction Services and Due Diligence at PwC. Before joining the Bamburgh Capital team, Michael spent 3 years as CFO of private energy support services company, Cenergist Limited, where he remains a shareholder. He was ranked No 1 stock picker, twice, in Europe for the Support Services sector by FTSE Starmine.
Stuart Sharp LL.B
Stuart qualified as a solicitor at respected Scottish firm Brodies, WS, after reading Law at Edinburgh University. His exceptional 30 year career in the investment industry began in Scotland with Aberdeen Trust. He then joined Yorkshire-based Rensburg Fund Management (now Franklin Templeton Investments) and was a founding member of its successful funds team. As Investment Director there for over 10 years he was instrumental in growing funds from £30 million to over £1 billion. He has won numerous UK investment industry awards for performance particularly in the Equity Income and UK Smaller Company sectors. Following retirement from fund management in 2012, Stuart founded his own trusted consultancy to provide specialist investment counsel to Family Offices, High Net Worth Individuals and Charitable Foundations. He joined Bamburgh Capital as a consultant in 2017.